Botulinum Toxin Therapy in Hidradenitis Suppurativa
Recruiting now
Conditions studied: Hidradenitis Suppurativa, Hyperhidrosis
In brief
This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.
Key facts
- Study ID
- NCT05403710
- Run by
- University of Massachusetts, Worcester
- People needed
- 20
- Starts
- 2022-06-07
- Expected to finish
- 2028-04-30
- Last updated by the study team
- 2026-08-07
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Massachusetts Chan Medical School — Worcester, Massachusetts, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.